Journal article

Recombinant activated factor VII for a warfarinised Jehovah's Witness with an acute subdural haematoma

Rimma Goldberg, Katharine J Drummond

JOURNAL OF CLINICAL NEUROSCIENCE | ELSEVIER SCI LTD | Published : 2008

Abstract

Recombinant activated factor VII (rFVIIa) (NovoSeven; Novo Nordisk A/S, Bagsvaerd, Denmark) is a haemostatic agent first developed for bleeding associated with haemophilia and trauma, but for which the indications continue to expand. Recent reports have suggested efficacy for various types of intracranial haemorrhage and for patients with abnormalities of coagulation. We report a warfarin-anticoagulated Jehovah's Witness patient with an acute subdural haematoma for whom rFVIIa was used perioperatively. The haematoma was surgically evacuated without excessive blood loss and the patient eventually made a good recovery, returning to independent self-care.